Pharmaceuticals

Global Multiple Myeloma Drugs Market Size Projected to Reach $29.44 Billion During the Forecast Period

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Multiple Myeloma Drugs Market Over The Five-Year Period 2025–2029?

The multiple myeloma drugs market size has shown substantial growth in recent years. It is anticipated to expand from $21.84 billion in 2024 to $23.03 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.4%. This historical growth can be attributed to several factors including improved diagnosis, successful clinical trials, a better understanding of disease biology, enhancements in healthcare infrastructure, increased patient advocacy, and broader awareness.

The multiple myeloma drugs market is anticipated to experience robust expansion over the coming years. By 2029, its valuation is projected to reach $29.44 billion, exhibiting a compound annual growth rate (CAGR) of 6.3%. This projected growth is driven by factors such as advancements in immunotherapy, the broadening of targeted therapies, new applications for liquid biopsy, the rise of car-t cell therapy, and ongoing biomarker discovery. Key trends expected during this period encompass a focus on long-term survivorship, research into epigenetic therapies, the increased utilization of telemedicine, wider availability of novel therapies, and an emphasis on sustainability within myeloma care.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11943&type=smp

What Are The Top Growth Drivers Impacting The Multiple Myeloma Drugs Market Outlook?

The rising incidence of hematological cancer is projected to propel the expansion of the multiple myeloma drugs market. These cancers originate in blood-forming tissues such as bone marrow or immune system cells, encompassing conditions like leukemia, lymphoma, and multiple myeloma. Medications for multiple myeloma work by targeting and restricting the growth of cancer cells, primarily by decreasing cell division through stimulating various enzymatic actions, and also by helping bones remain strong and alleviating pain in weakened bones. For instance, according to the American Cancer Society (ACS), a US-based health organization, approximately 59,610 newly diagnosed cases of leukemia were reported in January 2023, along with around 20,380 cases of acute myeloid leukemia (AML). Additionally, the total number of leukemia-related deaths reached 23,710. This underscores how the increasing prevalence of hematological cancer is driving the growth of the multiple myeloma drugs market.

How Is The Multiple Myeloma Drugs Market Segmented?

The multiple myeloma drugs market covered in this report is segmented –

1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types

2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Men, Women

Subsegments:

1) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib

3) By Histone Deacetylase Inhibitors: Panobinostat, Romidepsin

4) By Monoclonal Antibody Drugs: Daratumumab, Elotuzumab, Isatuximab

5) By Steroids: Dexamethasone, Prednisone

6) By Other Drug Types: Alkylating Agents, Antimetabolites, New Experimental Drugs

Which Trends Are Impacting The Multiple Myeloma Drugs Market?

Product innovation is a prominent and growing trend in the multiple myeloma drugs market. Companies at the forefront of the multiple myeloma drugs market are concentrating on developing groundbreaking products to solidify their standing and gain a competitive advantage. For instance, in March 2022, Janssen Biotech Inc., a Japan-based biotechnology company, secured United States Food and Drug Administration approval for Carvykti, a CAR T-Cell therapy (personalized immunotherapy) for multiple myeloma. CARVYKTI (ciltacabtagene autoleucel) is a genetically modified autologous cell-based product, comprising T cells transduced ex vivo with a replication-incompetent lentiviral vector that encodes an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR), which itself consists of two single domain antibodies linked to a 4-1BB costimulatory domain and a CD3-zeta signaling domain. Patients who have received four or more lines of therapy, including treatment with three critical kinds of multiple myeloma medications (an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody), are eligible to receive it for treating relapsed conditions.

Which Major Firms Are Strengthening Their Position In The Multiple Myeloma Drugs Industry?

Major companies operating in the multiple myeloma drugs market include Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG., Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company, Daiichi Sankyo Co. Ltd., Lonza Group AG, Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Biotest AG, Onyx Pharmaceuticals Inc., PharmaMar SA, Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., Oncopetides AB

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report

What Are The Regional Market Dynamics Impacting The Multiple Myeloma Drugs Industry?

North America was the largest region in the multiple myeloma drugs market in 2024. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Multiple Myeloma Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=11943&type=smp

Browse Through More Reports Similar to the Global Multiple Myeloma Drugs Market 2025, By The Business Research Company

Cardiovascular Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795